Next report date
—
Report period
—
EPS estimate
—
Revenue estimate
—
−0.356EUR
−86.89 MEUR
5.64 MEUR
124.43 M
About Precigen, Inc.
Sector
Industry
CEO
Helen Sabzevari
Website
Headquarters
Germantown
Employees (FY)
202
Founded
1998
FIGI
BBG005KBPQB4
Precigen, Inc. is a biotechnology company, which engages in the research and development of synthetic biology technologies. It operates through the following segments: Biopharmaceuticals, Exemplar, and Trans Ova. The Biopharmaceuticals segment is involved in advancing the next generation of gene and cell therapies using precision technology to target urgent and intractable diseases in immuno-oncology, autoimmune disorders, and infectious diseases. It also engages in pioneering a proprietary class of microbe-based biopharmaceuticals that enable expression and local delivery of disease-modifying therapeutics. The Exemplar segment is focused on developing research models and services for healthcare research applications. The Trans Ova segment provides bovine reproductive technologies. The company was founded by Thomas David Reed in 1998 and is headquartered in Germantown, MD.
Trade directly on the supercharts through our supported, fully-verified and user-reviewed brokers.
Frequently Asked Questions
Depending on the exchange, the stock ticker may vary. For instance, on FWB exchange PRECIGEN INC. stocks are traded under the ticker I5X.
PRECIGEN INC. is going to release the next earnings report on May 9, 2024. Keep track of upcoming events with our Earnings Calendar.
I5X earnings for the last quarter are −0.12 EUR per share, whereas the estimation was −0.07 EUR resulting in a −64.54% surprise. The estimated earnings for the next quarter are −0.08 EUR per share. See more details about PRECIGEN INC. earnings.
PRECIGEN INC. revenue for the last quarter amounts to 1.11 M EUR despite the estimated figure of 1.93 M EUR. In the next quarter revenue is expected to reach 1.37 M EUR.
Yes, you can track PRECIGEN INC. financials in yearly and quarterly reports right on TradingView.
I5X net income for the last quarter is −29.95 M EUR, while the quarter before that showed −18.73 M EUR of net income which accounts for −59.93% change. Track more PRECIGEN INC. financial stats to get the full picture.
No, I5X doesn't pay any dividends to its shareholders. But don't worry, we've prepared a list of high-dividend stocks for you.
Like other stocks, I5X shares are traded on stock exchanges, e.g. Nasdaq, Nyse, Euronext, and the easiest way to buy them is through an online stock broker. To do this, you need to open an account and follow a broker's procedures, then start trading. You can trade PRECIGEN INC. stock right from TradingView charts — choose your broker and connect to your account.
As of May 7, 2024, the company has 202.00 employees. See our rating of the largest employees — is PRECIGEN INC. on this list?
We've gathered analysts' opinions on PRECIGEN INC. future price: according to them, I5X price has a max estimate of 12.82 EUR and a min estimate of 5.49 EUR. Watch I5X chart and read a more detailed PRECIGEN INC. stock forecast: see what analysts think of PRECIGEN INC. and suggest that you do with its stocks.
EBITDA measures a company's operating performance, its growth signifies an improvement in the efficiency of a company. PRECIGEN INC. EBITDA is −74.52 M EUR, and current EBITDA margin is −1.32 K%. See more stats in PRECIGEN INC. financial statements.